Literature DB >> 3814459

Reversibility of primary pulmonary hypertension during six years of treatment with oral diazoxide.

N S Chan, J McLay, A C Kenmure.   

Abstract

A 32 year old woman presented with a syncopal attack and dyspnoea on exertion. A diagnosis of primary pulmonary hypertension was confirmed by clinical examination, cardiac catheterisation, and pulmonary angiography. Her symptoms resolved completely with oral diazoxide and the pulmonary arterial pressure was reduced to normal levels over a period of six years. When diazoxide was discontinued on two separate occasions pulmonary hypertension recurred. This demonstrated the continued presence of the underlying stimulus for vasoconstriction.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3814459      PMCID: PMC1277110          DOI: 10.1136/hrt.57.2.207

Source DB:  PubMed          Journal:  Br Heart J        ISSN: 0007-0769


  15 in total

1.  Pulmonary hypertension with special reference to the vasoconstrictive factor.

Authors:  P WOOD
Journal:  Br Heart J       Date:  1958-10

2.  Intracardiac infusion of acetylcholine in primary pulmonary hypertension.

Authors:  P SAMET; W H BERNSTEIN; J WIDRICH
Journal:  Am Heart J       Date:  1960-09       Impact factor: 4.749

3.  Sustained improvement in primary pulmonary hypertension during six years of treatment with sublingual isoproterenol.

Authors:  D A Pietro; K A LaBresh; R M Shulman; E D Folland; A F Parisi; A A Sasahara
Journal:  N Engl J Med       Date:  1984-04-19       Impact factor: 91.245

4.  Diazoxide in primary pulmonary hypertension.

Authors:  W P Klinke; J A Gilbert
Journal:  N Engl J Med       Date:  1980-01-10       Impact factor: 91.245

5.  A case of spontaneous resolution of idiopathic pulmonary hypertension.

Authors:  A Fujii; M Rabinovitch; E C Matthews
Journal:  Br Heart J       Date:  1981-11

6.  Verapamil in primary pulmonary hypertension.

Authors:  I Malcić; D Richter
Journal:  Br Heart J       Date:  1985-03

7.  Primary pulmonary hypertension: natural history and the importance of thrombosis.

Authors:  V Fuster; P M Steele; W D Edwards; B J Gersh; M D McGoon; R L Frye
Journal:  Circulation       Date:  1984-10       Impact factor: 29.690

8.  Hazards of diazoxide in pulmonary hypertension.

Authors:  J Buch; A Wennevold
Journal:  Br Heart J       Date:  1981-10

9.  Primary pulmonary hypertension: effects of nifedipine.

Authors:  F Camerini; E Alberti; S Klugmann; A Salvi
Journal:  Br Heart J       Date:  1980-09

10.  Regression of primary pulmonary hypertension.

Authors:  P D Bourdillon; C M Oakley
Journal:  Br Heart J       Date:  1976-03
View more
  5 in total

1.  Asymptomatic primary pulmonary hypertension associated with liver cirrhosis.

Authors:  K Murata; A Shimizu; K Takase; T Nakano; Y Tameda
Journal:  J Gastroenterol       Date:  1997-02       Impact factor: 7.527

2.  Rapid recurrence of pulmonary hypertension following cessation of nifedipine.

Authors:  M M Gallagher; C M Hart; C J Vaughan; W H Fennell
Journal:  Postgrad Med J       Date:  1998-02       Impact factor: 2.401

Review 3.  Clinical pharmacokinetics of vasodilators. Part I.

Authors:  R Kirsten; K Nelson; D Kirsten; B Heintz
Journal:  Clin Pharmacokinet       Date:  1998-06       Impact factor: 6.447

Review 4.  Implication of Potassium Channels in the Pathophysiology of Pulmonary Arterial Hypertension.

Authors:  Hélène Le Ribeuz; Véronique Capuano; Barbara Girerd; Marc Humbert; David Montani; Fabrice Antigny
Journal:  Biomolecules       Date:  2020-09-01

5.  Loss-of-Function ABCC8 Mutations in Pulmonary Arterial Hypertension.

Authors:  Michael S Bohnen; Lijiang Ma; Na Zhu; Hongjian Qi; Conor McClenaghan; Claudia Gonzaga-Jauregui; Frederick E Dewey; John D Overton; Jeffrey G Reid; Alan R Shuldiner; Aris Baras; Kevin J Sampson; Marta Bleda; Charaka Hadinnapola; Matthias Haimel; Harm J Bogaard; Colin Church; Gerry Coghlan; Paul A Corris; Mélanie Eyries; J Simon R Gibbs; Barbara Girerd; Arjan C Houweling; Marc Humbert; Christophe Guignabert; David G Kiely; Allan Lawrie; Rob V MacKenzie Ross; Jennifer M Martin; David Montani; Andrew J Peacock; Joanna Pepke-Zaba; Florent Soubrier; Jay Suntharalingam; Mark Toshner; Carmen M Treacy; Richard C Trembath; Anton Vonk Noordegraaf; John Wharton; Martin R Wilkins; Stephen J Wort; Katherine Yates; Stefan Gräf; Nicholas W Morrell; Usha Krishnan; Erika B Rosenzweig; Yufeng Shen; Colin G Nichols; Robert S Kass; Wendy K Chung
Journal:  Circ Genom Precis Med       Date:  2018-10
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.